Clinical Trials & Emerging Therapies
Current clinical trials are exploring approaches that address the root drivers of the disease, including neutrophilic inflammation, mucus viscosity, and airway damage.
For decades, bronchiectasis care has centered on managing symptoms such as clearing mucus, preventing infections, and keeping the lungs as healthy as possible. The FDA’s recent approval of Brinsupri™, the first therapy ever approved for non-cystic fibrosis bronchiectasis, represents a true turning point. It demonstrates that targeted treatments are possible and that more breakthrough therapies are on the way.
Clinical Trials & Emerging Therapies: Index
Emerging Therapies | Precision Medicine | Drugs in Clinical Trials | Why Clinical Trials Matter | Common Questions | Key Points
Emerging Therapies: A Hopeful Future
On August 12, 2025, the FDA approved Brinsupri™ for people 12 years of age and older who have non-cystic fibrosis bronchiectasis. Brinsupri™ is the first FDA-approved treatment for non-cystic fibrosis bronchiectasis, and its arrival marks a true turning point for our community.
For many years, people living with bronchiectasis have relied on treatments that were helpful but not specifically approved for this disease. Brinsupri™ changes that reality. This medication is designed to help reduce exacerbations by addressing the inflammatory pathways that contribute to ongoing airway damage.
Its approval reflects years of scientific progress and brings new hope to individuals who are seeking better control, fewer flare-ups, and a stronger quality of life.
Precision Medicine: Toward Treatment That Fits You
Bronchiectasis is not one disease that behaves the same way in everyone. Two people with similar CT scans can grow different bacteria, have different types of inflammation, and respond very differently to the same treatment. Precision medicine aims to understand those differences so that treatment can be matched to the individual, instead of relying on “try it and see.”
Researchers are studying several clues, sometimes called treatable traits: the organisms and microbial balance in your airways, neutrophilic inflammation (including markers such as neutrophil elastase), type 2 or eosinophilic inflammation, and underlying causes. Brinsupri™ is an early example of this shift, because it targets a specific inflammatory pathway rather than only treating symptoms.
Most of these tests are still used mainly in research, not in routine appointments. But knowing your own sputum results, blood work, underlying cause and exacerbation history can help you have more informed conversations with your bronchiectasis specialist.
Learn more: Precision Medicine in Bronchiectasis: Why One Size Doesn’t Fit All
Drugs in Clinical Trials
Promising therapies represent a shift in how we think about bronchiectasis, not just as a condition to manage, but as one we may one day be able to slow down or modify more directly. Staying connected with your care team and trusted resources can help you understand when these options become available and whether participating in a clinical trial is right for you.
Here are some of the therapies currently being studied:
Arina‑1 (Renovion):
A nebulized therapy that thins mucus, clears the lungs, and acts as an anti-inflammatory agent.
Gremubamab (AstraZeneca)
An anti‑inflammatory monoclonal antibody under investigation in the GREAT‑2 trial for people with bronchiectasis and Pseudomonas aeruginosa.
HSK31858 (Haisco/Chiesi)
ADPP1 inhibitor in early‑stage trials, aiming to reduce neutrophil‑driven airway damage.
Verducatib BI 1291583 (Boehringer Ingelheim)
A DPP1/CatC inhibitor, currently being evaluated in the AIRTIVITY® study.
Why Clinical Trials Matter
Bronchiectasis has long lacked an approved, disease‑modifying treatment. Clinical trials are changing that narrative, offering access to innovative therapies while helping shape the future of care.
Many drugs in development target airway inflammation, neutrophil overactivity, mucus hypersecretion, and infection risk. By participating in a trial, you can:
Gain possible early access to promising therapies before they’re widely available.
Contribute to research that may benefit others with bronchiectasis in the future.
Receive close medical monitoring and frequent check‑ins with a specialized research team.
Feel more informed, empowered, and proactive in managing your condition.
If you’re interested in learning more, talk to your pulmonologist or visit ClinicalTrials.gov to explore ongoing studies near you
Common Questions
-
Many of the therapies in development aim to reduce neutrophilic inflammation, improve mucus clearance, and protect or repair airway structure. The hope is to slow or stop disease progression rather than just manage symptoms.
-
Every clinical trial has specific eligibility criteria, such as age, disease severity, or infection status. If you’re interested, speak with your pulmonologist to see if you qualify and whether participation would fit your personal health goals.
-
Benefits can include early access to cutting-edge therapies, close monitoring and follow-up by research teams, and the opportunity to contribute to medical knowledge and help others in the bronchiectasis community.
-
Clinical trials are designed with safety as a top priority, and participants are monitored closely for side effects or complications. All trials must follow strict ethical and regulatory standards.
Key Points to Remember
Emerging therapies and clinical trials are giving us reason to hope for the future of bronchiectasis care. While these treatments are still in development, staying informed and working closely with your care team can help you prepare to take advantage of new options as they become available. Clinical trials are not just about research; they’re about empowering patients to be part of progress.